people worldwide, is one of the leading causes of morbidity and has
a significant economic cost. Although the mechanisms of action are not well understood, antidepressants, including serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have
been used for the treatment of depression, anxiety and other
psychiatric disorders.1 Here we identified a Wnt signaling inhibitor, secreted frizzled-related protein (sFRP3), as a molecular target of
antidepressant treatments in rodent models, and revealed the significant association of three single-nucleotide polymorphisms
(SNPs) in FRZB (the sFRP3 human ortholog) with early antidepressant
responses in a clinical cohort.